---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-165903"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:52:19.730266+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics enters ATM equity offering agreement for up to $350M

## Summary
- Filed prospectus supplement registering up to $350M in common stock sales.
- Agents Leerink Partners and Cantor Fitzgerald will receive 3.0% commission per share sold.
- No minimum sales required; sales made via 'at-the-market' methods under Rule 415.
- Agreement dated June 21, 2024; no escrow or trust arrangement.

## SEC filing metadata
- accession: 0001193125-24-165903
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/0001193125-24-165903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/d781699d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-165903
- JSON: https://secwatch.observer/filing/0001193125-24-165903.json
- Plain text: https://secwatch.observer/filing/0001193125-24-165903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.